title: Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
abstract: BACKGROUND
  Non-invasive imaging biomarkers of cellular proliferation hold great promise for quantifying response to personalized medicine in oncology. An emerging approach to assess tumor proliferation utilizes the positron emission tomography (PET) tracer 3'-deoxy-3'[(18)F]-fluorothymidine, [(18)F]-FLT. Though several studies have associated serial changes in [(18)F]-FLT-PET with elements of therapeutic response, the degree to which [(18)F]-FLT-PET quantitatively reflects proliferative index has been continuously debated for more that a decade. The goal of this study was to elucidate quantitative relationships between [(18)F]-FLT-PET and cellular metrics of proliferation in treatment naïve human cell line xenografts commonly employed in cancer research.
  
  
  RESULTS
  [(18)F]-FLT-PET was conducted in human cancer xenograft-bearing mice. Quantitative relationships between PET, thymidine kinase 1 (TK1) protein levels and immunostaining for proliferation markers (Ki67, TK1, PCNA) were evaluated using imaging-matched tumor specimens. Overall, we determined that [(18)F]-FLT-PET reflects TK1 protein levels, yet the cell cycle specificity of TK1 expression and the extent to which tumors utilize thymidine salvage for DNA synthesis decouple [(18)F]-FLT-PET data from standard estimates of proliferative index.
  
  
  CONCLUSIONS
  Our findings illustrate that [(18)F]-FLT-PET reflects tumor proliferation as a function of thymidine salvage pathway utilization. Unlike more general proliferation markers, such as Ki67, [(18)F]-FLT PET reflects proliferative indices to variable and potentially unreliable extents. [(18)F]-FLT-PET cannot discriminate moderately proliferative, thymidine salvage-driven tumors from those of high proliferative index that rely primarily upon de novo thymidine synthesis. Accordingly, the magnitude of [(18)F]-FLT uptake should not be considered a surrogate of proliferative index. These data rationalize the diversity of [(18)F]-FLT-PET correlative results previously reported and suggest future best-practices when [(18)F]-FLT-PET is employed in oncology.
authors.affiliation: Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
authors.forename: Eliot T
authors.initials: ET
authors.lastname: McKinley
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Ayers
authors.forename: R Adam
authors.initials: RA
authors.lastname: Smith
authors.forename: Samir A
authors.initials: SA
authors.lastname: Saleh
authors.forename: Ping
authors.initials: P
authors.lastname: Zhao
authors.forename: Mary Kay
authors.initials: MK
authors.lastname: Washington
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Coffey
authors.forename: H Charles
authors.initials: HC
authors.lastname: Manning
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015224:Dideoxynucleosides / Q000378:metabolism; D004195:Disease Models, Animal; D045325:HCT116 Cells; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D009154:Mutation; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D049268:Positron-Emission Tomography; D013936:Thymidine / Q000378:metabolism; D014183:Transplantation, Heterologous
chemical_list: D015415:Biomarkers; D015224:Dideoxynucleosides; C002854:alovudine; D013936:Thymidine
references.citation: J Nucl Med. 2001 Apr;42(4):636-45
references.pmid: 11337554
references.citation: Cancer Res. 2006 Nov 15;66(22):11055-61
references.pmid: 17108145
references.citation: Chest. 2006 Feb;129(2):393-401
references.pmid: 16478857
references.citation: Cancer Res. 2005 Nov 1;65(21):10104-12
references.pmid: 16267037
references.citation: Cancer Res. 1995 Nov 15;55(22):5187-90
references.pmid: 7585571
references.citation: Cancer Res. 2003 May 15;63(10):2681-7
references.pmid: 12750297
references.citation: J Nucl Med. 2009 Nov;50(11):1857-64
references.pmid: 19837754
references.citation: Clin Cancer Res. 2007 Jun 15;13(12):3460-9
references.pmid: 17575208
references.citation: Nucl Med Biol. 2000 Feb;27(2):143-56
references.pmid: 10773543
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Oct 15;879(28):2963-70
references.pmid: 21925976
references.citation: Cancer Res. 2003 Dec 1;63(23):8558-9; author reply 8560
references.pmid: 14679027
references.citation: Clin Cancer Res. 2008 Nov 15;14(22):7413-22
references.pmid: 19010858
references.citation: Cancer Res. 1992 Feb 15;52(4):917-23
references.pmid: 1737355
references.citation: Ann Nucl Med. 2012 Nov;26(9):757-63
references.pmid: 22821337
references.citation: J Nucl Med. 1997 Feb;38(2):280-7
references.pmid: 9025756
references.citation: Eur J Nucl Med Mol Imaging. 2004 May;31(5):720-4
references.pmid: 14991243
references.citation: J Nucl Med. 1998 Oct;39(10):1757-62
references.pmid: 9776283
references.citation: J Nucl Med. 2006 Oct;47(10):1612-21
references.pmid: 17015896
references.citation: Pharmacol Ther. 1995;67(2):155-86
references.pmid: 7494863
references.citation: J Nucl Med. 2005 Jun;46(6):945-52
references.pmid: 15937304
references.citation: J Nucl Med. 2003 Dec;44(12):2027-32
references.pmid: 14660729
references.citation: J Nucl Med. 2005 Mar;46(3):400-4
references.pmid: 15750150
references.citation: Science. 1998 Nov 20;282(5393):1497-501
references.pmid: 9822382
references.citation: Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):653-9
references.pmid: 15711980
references.citation: J Nucl Med. 2011 Aug;52(8):1181-8
references.pmid: 21764789
references.citation: Cancer Res. 2002 Jun 15;62(12):3331-4
references.pmid: 12067968
references.citation: J Nucl Med. 2008 Dec;49(12):2057-66
references.pmid: 18997037
references.citation: Cancer Res. 2003 Jul 1;63(13):3791-8
references.pmid: 12839975
references.citation: Gut. 2003 Nov;52(11):1602-6
references.pmid: 14570730
references.citation: Anticancer Res. 2006 Sep-Oct;26(5A):3467-72
references.pmid: 17094468
references.citation: Clin Cancer Res. 2012 Mar 1;18(5):1303-12
references.pmid: 22170262
references.citation: Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1610-6
references.pmid: 17530250
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1099-110
references.pmid: 21245090
references.citation: Clin Cancer Res. 2009 Jul 15;15(14):4712-21
references.pmid: 19584166
references.citation: Nucl Med Biol. 2004 Oct;31(7):829-37
references.pmid: 15464384
references.citation: J Nucl Med. 2005 Feb;46(2):371-80
references.pmid: 15695799
references.citation: Nat Med. 1998 Nov;4(11):1334-6
references.pmid: 9809561
references.citation: Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1407-12
references.pmid: 12898201
references.citation: In Vitro Cell Dev Biol. 1993 Mar;29A(3 Pt 1):239-48
references.pmid: 8385096
references.citation: J Nucl Med. 1996 Feb;37(2):290-6
references.pmid: 8667064
references.citation: Nucl Med Commun. 2009 Nov;30(11):841-5
references.pmid: 19773672